The prognostic significance of indoleamine-2,3- Dioxygenase and the recepto rs for transforming growth facto r β and interferon γ in metastatic lymph nodes in malignant melanoma

Polish Journal of Pathology

Volumn 66, Issue 4, 2015, Pages 376-382

  Pelak, Maciej J ^a   Śnietura, Mirosław ^a   Lange, Dariusz ^a   Nikiel, Barbara ^a   Pecka, Katarzyna M ^b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Immunohistochemistry; Indoleamine pyrrole 2,3, dioxygenase; Interferon ; Melanoma; Transforming growth factor

Indexed keywords

GAMMA INTERFERON RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADULT; AGED; ENZYMOLOGY; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MALE; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RECEPTORS, INTERFERON; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84957103283     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/pjp.2015.57249     Document Type: Article

References (29)

1. Salama AK, de Rosa N, Scheri RP, et al. Hazard-rate analysis and patterns of recurrence in early stage melanoma: Moving towards a rationally designed surveillance strategy. PLoS ONE 2013; 8: e57665.
2. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow- up guidelines. J Clin Oncol 2010; 28: 3042-3047.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 2009; 27: 6199-6206.
4. Hodi FS, O’Day SJ, A McDermott, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
5. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-1030.
6. Munn, DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005; 22: 633-642.
7. Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196: 459-468.
8. Munn, DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-1193.
9. Lob S, Konigsrainer A, Rammensee H-G, et al. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009; 9: 445-452.
10. Piek E, Heldin C-H, ten Dijke P. Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 1999; 13: 2105-2124.
11. Massagué J. TGF-β in cancer. Cell 2008; 134: 215-230.
12. Schroeder K, Hertzog J, Ravasi T, Hume DA. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163-189.
13. Meyskens FL Jr, Kopecky KJ, Taylor CW, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst 1995; 87: 1710-1713.
14. Chevolet I, Speeckaert R, Haspeslagh M, et al. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control? Br J Dermatol 2014; 171: 987-995.
15. Speeckaert R, Vermaelen K, van Geel N, et al. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer 2011; 48: 2004-2011.
16. Lee JR, Dalton RR, Messina JL, et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003; 83: 1457-1466.
17. Pallotta MT, Orabona C, Volpi C, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011; 12: 870-878.
18. Murakami Y, Hoshi M, Imamura Y, et al. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: Potential role in macrophage-mediated inflammatory diseases. Med Inflam 2013; 2013: 391984.
19. Lee YH, Chen Y, Chan LJ, et al. Molecular analysis of melanoma- induced sentinel lymph node immune dysfunction. Cancer Immunol Immunother 2011; 60: 685-692.
20. Kariminia A, Ardestani SK, Al-Sadat Ardestani N, et al. Interferon gamma unresponsiveness due to down-regulation of IFN-γR expression in experimental cutaneous leishmaniasis. Iran Biomed J 2006; 10: 105-109.
21. Jurukovski V, Dabović B, Todorović V, et al. Methods for measuring TGF-β using antibodies, cells, and mice. Meth Mol Med 2005; 117: 161-175.
22. Javelaud D, Alexaki V-I, Mauviel A. Transforming growth factor- b in cutaneous melanoma. Pigment Cell Melanoma Res 2008; 21: 123-132.
23. Taylor CR, Levenson RM. Quantification of immunohistochemistry- issues concerning methods, utility and semiquantitative assessment II. Histopathology 2006; 49: 411-424.
24. Rizzardi AE, Johnson AT, Vogel RI et al. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012; 7: 42.
25. de Matos PS, Ferreira AP, de Oliveira Facuri F, et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005; 47: 391-401.
26. Wainwright DA, Chang AL, Dey M, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014; 20: 5290-5301.
27. National Institute of Health Clinical Trial Registry; ref. no. NCT02073123: www.clinicaltrials.gov/ct2/show/ NCT02073123?term=indoximod&rank=5; accessed 23rd July 2015.
28. Gibney GT, Hamid O, Gangadhar TC, et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J Clin Oncol 2014; 32 (5s): 3010.
29. Nayak A, Hao Z, Sadek R, et al. A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors. J Immunotherapy of Cancer 2014; 2 (Suppl. 3): P250.